RIGI and cancer: LRRC25-mediated immune evasion may play a critical role in RIG-I-dependent cancers(e.g., melanoma, colorectal cancer, and non-small cell lung cancer), suggesting that combining LRRC25 inhibition with ICIs could enhance therapeutic outcomes in these contexts43,44.